Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 7/20 | 0.54 |
| ▸ | EGFR | P00533 | 7/20 | 0.51 |
| ▸ | SYK | P43405 | 3/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411594 | 0.92 | BRD4 (0.58) | ALKLRRK2BRD4JAK2 | |
| SCHEMBL5408196 | 0.92 | MEN1 (0.54) | ALKLRRK2BRD4JAK2 | |
| SCHEMBL5410626 | 0.91 | MEN1 (0.56) | ALKLRRK2BRD4JAK2 | |
| SCHEMBL5409983 | 0.91 | MEN1 (0.56) | ALKLRRK2BRD4JAK2 | |
| SCHEMBL5405395 | 0.89 | LRRK2 (0.51) | ALKLRRK2BRD4JAK2 | |
| SCHEMBL5416251 | 0.89 | LRRK2 (0.60) | ALKLRRK2JAK2 | |
| SCHEMBL5415948 | 0.84 | HDAC3 (0.49) | ALKEGFRLRRK2BRD4JAK2 | |
| SCHEMBL5408198 | 0.83 | HDAC3 (0.48) | ALKSYKLRRK2BRD4JAK2 | |
| SCHEMBL5416137 | 0.81 | HDAC3 (0.46) | ALKEGFRLRRK2BRD4JAK2 | |
| SCHEMBL5415421 | 0.81 | STK17A (0.48) | ALKSYKLRRK2BRD4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166599-B2 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-23 | — | — | US | claimed |
| US-20050090486-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-04-28 | — | — | US | claimed |
| US-20030134838-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-17 | — | — | US | claimed |
| US-7166599-B2 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-23 | — | — | US | disclosed |
| US-20050090486-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-04-28 | — | — | US | disclosed |
| US-20030134838-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134838-A1 | Trisubstituted pyrimidines | APP, PSEN1, BACE1 | ALK 3651/4885EGFR 3316/4885SYK 1842/4885 |
| US-20050090486-A1 | Trisubstituted pyrimidines | APP, BACE1, PSEN1 | ALK 2986/4885EGFR 3952/4885SYK 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.